Iraqi Journal of Scientific and Industrial Research
Volume 4, Issue 3, July-September 2025, pp. 74-76

Resistance Patterns of *Staphylococcus aureus* Towards Antibiotics

Duaa R. Ibraheem

Department of Chemistry, College of Education, Al-Iraqia University, Baghdad, IRAQ

Abstract
Our study highlights the importance of monitoring antibiotic resistance patterns and selecting appropriate antibiotics for the treatment of Staphylococcus aureus infections. The high resistance rates observed in third-generation cephalosporin emphasize the need for alternative treatment strategies and the judicious use of antibiotics to prevent further resistance development. Further research is warranted to explore novel antibiotic combinations and alternative therapies to combat antibiotic-resistant S. aureus infections

Keywords: Ciprofloxacin, Levofloxacin, Amikacin, Ceftizoxime
Received: 8 April 2025; **Revised:** 14 May 2025; **Accepted:** 21 May 2025; **Published:** 1 July 2025

1. Introduction

Staphylococcus aureus, a ubiquitous human pathogen, as *Escherichia coli* [1], it exhibits a remarkable capacity to develop resistance against a wide array of antibiotics, posing a significant challenge to effective clinical treatment [2]. The adaptability of *S. aureus* to resist antibiotics is a critical area of concern, given its intrinsic virulence and ability to cause life-threatening infections [3]. The global rise in antibiotic resistance necessitates a comprehensive understanding of resistance patterns and mechanisms to guide appropriate antibiotic usage and develop novel therapeutic strategies [3]. The emergence and spread of antibiotic resistance in microorganisms, particularly human pathogens, have been accelerated by the introduction and increasing use of antibiotics for antibacterial therapy [4]. The ability of *S. aureus* to develop resistance to virtually all available classes of antibiotics underscores the urgency of continuous surveillance and the development of alternative therapeutic approaches [5]. Analyzing antibiotic susceptibility patterns, resistance rates, and effectiveness can offer insights into optimizing treatment strategies and minimizing the spread of resistance. The ongoing battle against *S. aureus* infections necessitates a thorough understanding of the mechanisms of resistance and the judicious use of existing antimicrobial agents. This article presents the findings of a susceptibility study conducted on *S. aureus* isolates, highlighting both promising antibiotic options and concerning resistance trends.

2. Methods

A total of 15 *S. aureus* isolates were collected from clinical samples of Yarmouk Teaching Hospital and Medical City hospitals. The isolates were tested against nine commonly prescribed antibiotics, including ciprofloxacin, levofloxacin, amikacin, ceftriaxone, ceftazidime, ceftizoxime, amoxicillin-clavulanic acid, meropenem, and vancomycin. The antibiotic susceptibility of the isolates was determined using the Kirby-Bauer disk diffusion method, and the results were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [6].

3. Results

The average inhibition zone diameters for each antibiotic were calculated, and the antibiotics were ranked by their effectiveness when they worked (excluding resistant cases). Ciprofloxacin led with an average inhibition zone of 13.82 mm, followed by levofloxacin with an average of 11.54 mm.



Fig. (1) Heat-map shows the inhibition zone diameters for all 15 isolates against 9 antibiotics. Dark red indicates resistance (0 mm), green shows high effectiveness

Amikacin was unique, with a 0% resistance rate across all isolates, indicating a 100% effectiveness rate. Concerning resistance patterns, ceftriaxone and ceftazidime showed alarming resistance rates of 86.7%, followed by ceftizoxime that had a resistance rate of 73.3%. The overall resistance rate across all tests was 47.4%.



Fig. (2) Average Antibiotic Effectiveness



Fig. (3) Resistance Patterns (resistance percentages for each antibiotic, highlighting which drugs face the biggest challenges)



Fig. (4) Most and Least Effective antibiotics Comparison

4. Discussion

Our investigation into the antibiotic susceptibility of *S. aureus* isolates reveals a complex landscape of resistance patterns, highlighting both concerning trends and potential therapeutic options. Indeed, Antibiotic resistance is a growing global health crisis, threatening our ability to treat common infections and potentially reversing decades of progress in medicine. Understanding the current landscape of antibiotic effectiveness and resistance is crucial for guiding treatment strategies and developing new interventions. This article delves into a recent dataset highlighting the efficacy of specific antibiotics and alarming resistance patterns observed, providing insights into the challenges we face in combating bacterial infections. Our analysis reveals a mixed bag of results. On one hand, some antibiotics demonstrate good efficacy against tested isolates, while others show concerningly high levels of resistance. Specifically, Ciprofloxacin emerges as a leading contender, exhibiting an average inhibition zone of 13.82 mm when effective. Levofloxacin follows closely behind with an average effectiveness measured at 11.54 mm. These fluoroquinolones, known for their broad-spectrum activity and ability to inhibit DNA gyrase and topoisomerase IV, may still be viable options for treating certain infections [7]. However, it is critical to note that this is when they are effective - the overall resistance rates to these drugs, while not explicitly stated in the initial data, should be carefully considered.

A particularly encouraging finding is the 100% effectiveness rate of Amikacin across all tested isolates. This aminoglycoside antibiotic, which inhibits protein synthesis by binding to the 30S ribosomal subunit [8], remains a valuable tool in our arsenal. The absence of resistance suggests that Amikacin may be reserved as a last-line defense against multi-drug resistant bacteria, although prudent use is essential to prevent the emergence of resistance in the future. This is particularly important as aminoglycosides are often associated with nephrotoxicity and ototoxicity, necessitating careful monitoring during treatment [9]. However, the data also paints a worrying picture of widespread resistance. Ceftriaxone and Ceftazidime, both cephalosporin antibiotics, exhibit alarmingly high resistance rates of 86.7%. Ceftixime, another cephalosporin, also demonstrates a problematic resistance rate of 73.3%. These high resistance rates severely limit the clinical utility of these drugs, particularly in settings where antibiotic susceptibility testing is not readily available. The rise in cephalosporin resistance is concerning as these drugs are often used as first-line treatments for a variety of infections. The common mechanism of resistance is often the production of extended-spectrum beta-lactamases (ESBLs) or AmpC beta-lactamases, enzymes that hydrolyze the beta-lactam ring of cephalosporins, rendering them ineffective [10].

The overall resistance rate of 47.4% across all tests further underscores the magnitude of the problem. This high overall resistance rate has serious implications for public health and highlights the urgent need for action. The consequences of widespread antibiotic resistance include increased morbidity and mortality, prolonged hospital stays, and higher healthcare costs [11].

Indeed, the observed resistance patterns highlight several key areas of concern; Overuse and Misuse of Antibiotics: The high resistance rates to Ceftriaxone, Ceftazidime, and Ceftixime strongly suggest that these antibiotics are either being overused or inappropriately prescribed. Inappropriate antibiotic use, such as prescribing antibiotics for viral infections or using broad-spectrum antibiotics when a narrowspectrum agent would suffice, contributes directly to the selection and spread of resistant bacteria [12].

The findings emphasize the critical role of antibiotic stewardship programs in hospitals and other healthcare settings. These programs aim to optimize antibiotic use through education, guidelines, and monitoring, ultimately reducing the selective pressure that drives resistance [13]. That well be need for novel Antibiotics and Alternative Therapies: The increasing prevalence of antibiotic resistance underscores the urgent need for the development of new antibiotics with novel mechanisms of action. Furthermore, research into alternative therapies, such as phage therapy, immunotherapy, and antimicrobial peptides, is essential for providing clinicians with new tools to combat resistant infections [14].

Preventing the spread of resistant bacteria requires robust infection control practices, including hand hygiene, isolation of infected patients, and environmental cleaning. Effective infection control measures can significantly reduce the transmission of resistant organisms and limit the spread of antibiotic resistance [15].

Continuous surveillance of antibiotic resistance patterns is necessary to track the emergence and spread of resistant organisms. This information is crucial for informing treatment guidelines and developing effective strategies to combat resistance.

5. Conclusion

The data presented in this analysis provide a snapshot of the current state of antibiotic resistance, highlighting both promising avenues and alarming trends. While some antibiotics like Ciprofloxacin and Amikacin retain significant effectiveness, the high resistance rates observed with Ceftriaxone, Ceftazidime, and Ceftixime, coupled with the high overall resistance rate, emphasize the urgent need for a multi-pronged approach to combat antibiotic resistance. This approach must include promoting responsible antibiotic use, developing new antibiotics and alternative therapies, implementing robust infection control practices, and strengthening antibiotic surveillance programs. Failure to address this growing crisis will have devastating consequences for global health.

References

[1] Saad, S. M. Isolation and Diagnoses Escherichia coli from Patients at Hospital in Baghdad. *Iraqi J. Sci. Ind. Res.* **4**, 37–40 (2025).

[2] Pantosti, A., Sanchini, A. & Monaco, M. Mechanisms of antibiotic resistance in Staphylococcus aureus. *Future Microbiol.* **2**, 323–334 (2007).

[3] Ahmad, S., Raqeeb, A., Ali, F., Hameed, M. S. & Anwar, M. Characterization of novel antibiotic resistance genes in Staphylococcal aureus. *J. Bacteriol. Mycol.* **6**, 11–13 (2018).

[4] Berger-Bächi, B. Resistance mechanisms of gram-positive bacteria. *Int. J. Med. Microbiol.* **292**, 27–35 (2002).

[5] Vestergaard, M., Frees, D. & Ingmer, H. Antibiotic resistance and the MRSA problem. *Microbiol. Spectr.* **7**, 10–1128 (2019).

[6] Weinstein, M. P. & Lewis, J. S. The clinical and laboratory standards institute subcommittee on antimicrobial susceptibility testing: background, organization, functions, and processes. *J. Clin. Microbiol.* **58**, 10–1128 (2020).

[7] Hooper, D. C. Mechanisms of action of antimicrobials: focus on fluoroquinolones. *Clin. Infect. Dis.* **32**, S9–S15 (2001).

[8] Becker, B. & Cooper, M. A. Aminoglycoside antibiotics in the 21st century. *ACS Chem. Biol.* **8**, 105–115 (2013).

[9] Wenzler, E., Fraidenburg, D. R., Scardina, T. & Danziger, L. H. Inhaled antibiotics for gram-negative respiratory infections. *Clin. Microbiol. Rev.* **29**, 581–632 (2016).

[10] Bush, K., Jacoby, G. A. & Medeiros, A. A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrob. Agents Chemother.* **39**, 1211–1233 (1995).

[11] O'Neill, J. Tackling drug-resistant infections globally: final report and recommendations. (2016).

[12] Levy, S. B. & Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. *Nat. Med.* **10**, S122–S129 (2004).

[13] Barlam, T. F. *et al.* Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin. Infect. Dis.* **62**, e51–e77 (2016).

[14] Fair, R. J. & Tor, Y. Antibiotics and bacterial resistance in the 21st century. *Perspect. Medicin. Chem.* **6**, PMC-S14459 (2014).

[15] Siegel, J. D., Rhinehart, E., Jackson, M. & Chiarello, L. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Last update: July 2023. (2023).